Myxredlin is claimed to be the first and only ready-to-use insulin for intravenous (IV) infusion in the hospital and other acute care settings. It is provided with an The post FDA approves Baxter’s IV insulin Myxredlin appeared first on Pharmaceutical Business review.
Pregabalin Capsules had U.S. sales of approximately $5,497 million for the 12 months ending March 2019, according to IMS Health. Pregabalin Capsules are indicated for management of neuropathic The post Rising Pharmaceuticals announces the US launch of generic version of Pregabalin Capsules appeared first on Pharmaceutical Business review.
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment The post Novartis multiple sclerosis product Gilenya approved in China appeared first on Pharmaceutical Business review.
Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It is claimed to be the first and only approved The post Celgene gets FDA approval for Otezla to treat oral ulcers associated with Behçet’s Disease appeared first on Pharmaceutical Business review.
TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cells (oncolysis), the production of The post Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus appeared first on Pharmaceutical Business review.
“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Phase I/II study. Netherton Syndrome The post LifeMax receives rare pediatric disease designation for LM-030 to treat Netherton Syndrome appeared first on Pharmaceutical Business review.
The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure The post Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate appeared first on Pharmaceutical Business review.
As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be responsible for the development and commercialisation The post Astellas signs licensing deal for Frequency’s regenerative drug FX-322 appeared first on Pharmaceutical Business review.
AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superior Court of California County of The post AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs appeared first on Pharmaceutical Business review.
In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to The post PureTech acquires new clinical-stage programme LYT-100 to treat lymphedema appeared first on Pharmaceutical Business review.